Emergency Medicine Doctors in Jacksonvill, FL Accepting Medicare
1 Emergency Medicine doctors found. Showing 1 - 1
 Dr. Dylan Cahill Arnold, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: Bldg H 2005 Knight Lane, Navy Medicine Support Command, Dmhrsi Team, Jacksonvill, FL 32212 Phone: 757-635-4579 |
News Archive
Plants deliver: biofuels, medicines, bioplastics, flavours, pigments...
The need for a renewable and affordable source of carbon that can sustain future economic development without negatively impacting the environment is now widely recognised. It is also apparent that the increasingly high demand for fossil carbon will eventually deplete existing stocks.
Study may identify new diagnostics and treatment option for CVD
Forty-two percent of all deaths in the United States are related to cardiovascular disease. According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone.
Simple iron control mechanism can prevent development of severe forms of malaria
Malaria is a life-threatening condition that exposes approximately half of the world's population to the risk of developing a severe and often lethal form of disease. In a study published in the latest issue of the journal Cell Host & Microbe*, Miguel Soares and his team at Instituto Gulbenkian de Ci-ncia (IGC), Portugal, discovered that the development of severe forms of malaria can be prevented by a simple mechanism that controls the accumulation of iron in tissues of the infected host.
Study: Most pediatricians do not tell parents about early peanut introduction to prevent allergy
Guidelines to help parents introduce peanut-containing products to infants to prevent peanut allergies aren't being discussed. New research presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting shows pediatricians are not only not having the discussion, they're not referring high-risk babies for testing prior to peanut introduction.
Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis
Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.
› Verified 1 days ago